Ro 41-3399 is a novel orally active ester of Ro 40-6890, an aminothiazolyl cephalosporin with potent in vitro activities against commonly encountered aerobic gram-positive bacteria (streptococci and methicillin-susceptible staphylococci) and gram-negative bacteria (members of the family Enterobacteriaceae, haemophili, meningococci, and gonococci). In terms of the MICs determined by the methods recommended by the National Committee for Clinical Laboratory Standards, for 50 and 90%o of gram-positive organisms, the water-soluble free carboxylic acid Ro 40-6890 proved to be at least as active as or two-to fourfold more active than cefpodoxime, cefuroxime, cefaclor, amoxicillin, amoxicillin-clavulanic acid, and ceftriaxone; against aerobic gram-negative organisms, Ro 40-6890 was usually two-to fourfold more active than cefpodoxime, the next most potent of the oral drugs under comparison, but remained usually two-to fourfold weaker than ceftriaxone. Ro 40-6890 showed a high affinity for the essential penicillin-binding proteins of susceptible bacteria and was resistant to hydrolysis by a broad array of f-lactamases. Ro 41-3399 bopentil was well absorbed in mice when administered by oral gavage and proved effective in several experimental bacterial infections. Further studies with Ro 41-3399 and Ro 40-6890 are in progress.
Most potent cephalosporins are poorly absorbed from the human intestinal tract and are therefore suited only for parenteral use. However, some of these compounds can be rendered amenable to oral use by esterification of the C-4 carboxyl group of the dihydrothiazine ring. Examples are cefuroxime axetil (6, 14, 16) , cefpodoxime proxetil (5, 8) , and cefetamet pivoxil (1) . Structure-bioavailability relationship studies indicate that the nature of the alcohol used for derivatization has a major impact on the oral bioavailability of the ester. (Fig. 1B) .
Ro 41-3399 {(E)-2-(isobutoxycarbonyl)-2-pentenyl (6R,7R)-7-[(Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)
Ro 41-3399 was chosen for development from other esters of the free carboxylic acid Ro 40-6890 because of its higher oral bioavailability in rats (7) . In this paper, we describe the evaluation of the free carboxylic acid Ro 40-6890 in vitro and the in vivo activities of Ro 41-3399 as a hydrochloride salt in comparison with those of other oral ,3-lactams or their respective free carboxylic acids and ceftriaxone, a widely used parenteral aminothiazolyl cephalosporin. 
(B).
Chemical structures of Ro 41-3399 (A) and were used to study the effect of the medium on MICs. For broth tests, broth microdilution tests were performed as recommended by the NCCLS (12) .
Overnight cultures were diluted to a concentration of about 5 x 107 CFU/ml. Agar plates containing serial twofold dilutions of antibiotics were inoculated with the help of a multipoint inoculator (Denley A400) to yield about 1 x 104 to S x 104 CFU per spot; broth microdilution wells were inoculated with a multipipettor to yield about 1 x 104 to 5 x 104 CFU per well. Three reference strains, E. coli ATCC 25922, S. aureus ATCC 29213, and S. aureus ATCC 25923, were included in all parts of the study, as needed.
The inoculated plates were incubated for 18 h at 35°C in room air, except those for staphylococci, which were incubated for 24 h, and those for haemophili, gonococci, and pneumococci, which were incubated in a CO2 incubator (10% C02).
The MICs were read with the naked eye and defined as the lowest concentration of antibiotic that prevented clearly visible growth (a barely visible haze and the growth of five or fewer colonies per spot were disregarded). The interpretive criteria used for the comparative agents were those advocated by the NCCLS (13). 2 ,000 x g and 37C) with a Centrifree micropartition system (Amicon, Lexington, Mass.). The concentrations of Ro 40-6890 and comparative agents were 25, 50, and 250 ,ug/ml. Antibiotic and pooled plasma (2 ml) were allowed to equilibrate for 10 min at 37°C and pH 7.4 prior to centrifugation. The protein-free ultrafiltrate (0.1 ml) was assayed in triplicate by an agar well bioassay method. The indicator organism was E. coli 1346, and the medium was Antibiotic Medium no. 1 (Difco). A series of standards were prepared and incubated along with the unknowns. Inhibition diameters for the filtrate (Cf), the spiked plasma (Cp) and, as a control, the antibiotic solution used to spike the plasma were plotted on a graph that allowed extrapolation of the results for the unknown nonprotein-bound fraction of the antibacterial agent. The percentage of "free" drug in the filtrate was calculated as (Cf/Cp) x 100, and the percentage of plasma protein-bound drug was calculated as [1 - c Penicillin MIC, 20.12 pg/ml. d C. diphtheriae (n = 1), C pseudod4phthenticum (n = 3), C. equi (n = 1), and C. haemolyticum (n = 3). readily inhibited by the new oral aminothiazolyl cephalospocloacae, and Serratia marcescens, were highly resistant to rin and its congeners but not by most of the older comall compounds tested, whereas bacterial isolates that did not pounds. There were some exceptions; for example, cefaclor express these enzymes were highly susceptible to Ro 40-had good activity against K oxytoca. For representative (Tables 1 and 2 ). PBP 3 and shigellae (data not shown), and species of the family Vibri-PBP la were the targets inhibited by the lowest concentraonaceae other than Vibrio cholerae, Ro 40-6890 MICgos tions. Cefpodoxime had 50% inhibitory concentrations were <0.5 ,g/ml. In contrast, the activities of Ro 40-6890 (IC50s) slightly higher than those of Ro 40-6890, as did were poor (MIC90s, .64 ,ug/ml) against non-glucose-fer-cefuroxime. Cefaclor had the highest IC50s and distinctly the menting gram-negative rods and notably uniformly poor lowest affinities of the 1-lactams tested. For the S. aureus against Acinetobacter spp. and P. aeruginosa (data not PBPs (Table 5 ), the largest difference in affinities between Ro shown).
40-6890 and ceftriaxone was found for PBP 3. Enterobacteriaceae and P. aensginosa (Table 6 ). It was TEM-2 ,3-lactamases (see below) was the high potency of recognized with a high affinity (Km, 0.5 to 5 nM) but was this compound (MIC90, 0.06 ,ug/ml) against penicillinase-hydrolyzed slowly (kC,, 0.008 to 0.02 s-1). This stability was producing Neisseria gonorrhoeae, which readily hydrolyzed comparable to that of ceftriaxone (k.,, -0.01 to 0.05 s-1) in amoxicillin (MIC90, >64 p,g/ml). Chromosomally mediated the presence of these enzymes. (Table 3) for behavior was similar to those of these enzymes with ceftricommon pathogens. MIC test results obtained on MHA axone, although the latter cephalosporin was hydrolyzed were highly reproducible with the standard reference strains more rapidly. The extended broad-spectrum ,-lactamases E. coli ATCC 25922 and S. aureus ATCC 29213, more so produced by E. coli (for example, TEM-3) actively hydrothan with S. aureus ATCC 25923 ( teriaceae, except for C. freundi and E. cloacae isolates, which harbor chromosomally mediated group 1 ,B-lactamases, were susceptible to Ro 40-6890. The MIC50s of 1 and 0.5 p,g/ml for methicillin-susceptible isolates of S. aureus and coagulase-negative staphylococci suggest that methicillinsusceptible staphylococci may be included in the antibacterial spectrum of Ro 41-3399. The compound is also very active against streptococci and other respiratory tract pathogens, except for the highly penicillin-resistant pneumococci and the enterococci (data not shown).
Ro 40-6890 is similar to other aminothiazolyl cephalosporins with respect to inhibitory properties, affinities for PBPs, and resistance to the hydrolytic action of ,B-lactamases of groups 2b and 2e, based on the classification by Bush (2). It was bactericidal at concentrations equal to or slightly higher than the MIC, in accordance with the fact that PBP 3 is the preferential target in E. coli. Like other aminothiazolyl cephalosporins (3, 9) , Ro 40-6890 was stable against the action of different types of ,-lactamases, with the exception of group 1 1-lactamases and extended broad-spectrum (group 2b') 1-lactamases. The 
